G-SPACE INC

Sunnyvale, CA · Biotech · Private

Microgravity-based AI platform for real-time drug discovery and cellular analysis, integrating space experimentation with predictive algorithms to accelerate therapeutic development

Claim this profile

Follows are private to you and power your alerts

Updated · g-space.com

Sector
Biotech
Headquarters
Sunnyvale, CA
Total capital
$561K
Federal grants
$526K
3 awards · 2020–2023
Rank in peer group#24 of 48
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$35K
1 award · NASA
Rank in Biotech#363 of 4373
Granted patents
0
3 pending

Capital timeline

2020202120222023FEDERAL ↑EQUITY ↓Cumulative $561K$245K$125K$35K$156K
2020202120222023FEDERAL ↑EQUITY ↓Cumulative $561K$245K$125K$35K$156K

Latest events

  • Federal grantNASA · Phase I · Feasibility study for an automated Machine Learning analytics platform applied to muscle tissue chips in-space manufacturing process control$156K
  • Federal contractNASA · Asessment And Optimization Of PK-4 Data For Publication$35K
  • Federal grantNASA · Phase I · ATOM - An AI Environment for New Microgravity Materials Development$125K
  • Federal grantNSF · Phase I · SBIR Phase I: The role of gravity in advanced materials manufacturing for the era of digital transformation$245K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 48 peers

Line = median

Biotech · Platform

  • Federal grants#24 · top 50%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 3
  • PendingMethod For The Discovery And Design Of New Materials Without The Gravitational ForceUSPTOApplication 18707086
  • PendingMethod For The Discovery And Design Of New Materials Without The Gravitational ForceUSPTOApplication PCTUS2022079306
  • PendingMethod For The Discovery And Design Of New Materials Without The Gravitational ForceUSPTOApplication 63263662
  • G-SPACE, INCShares a founder: Ioana Cozmuta
  • Vaxxinity, Inc.Similar federal contract value in Biotech · $39K in contracts
  • CELL BIOLOGICS INCSimilar federal contract value in Biotech · $37K in contracts
  • EPIGENOME TECHNOLOGIES, INC.Similar federal contract value in Biotech · $35K in contracts
  • Epicypher, Inc.Similar federal contract value in Biotech · $33K in contracts
  • Day One BiopharmaceuticalsSimilar federal contract value in Biotech · $26K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .